Medpace (NASDAQ:MEDP) Price Target Raised to $609.00

Medpace (NASDAQ:MEDP) had its price target raised by Truist Financial from $462.00 to $609.00 in a research report released on Friday morning,Benzinga reports. They currently have a hold rating on the stock.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and lifted their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Mizuho upped their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday. Finally, Robert W. Baird boosted their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $560.92.

Medpace Stock Performance

Medpace stock opened at $601.38 on Friday. The company has a market capitalization of $16.78 billion, a price-to-earnings ratio of 35.25, a PEG ratio of 2.68 and a beta of 1.15. Medpace has a 12 month low of $373.00 and a 12 month high of $677.90. The stock’s 50 day moving average is $492.09 and its 200-day moving average is $493.84.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts predict that Medpace will post 17.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

A number of large investors have recently bought and sold shares of MEDP. Allspring Global Investments Holdings LLC raised its position in Medpace by 164.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock valued at $2,086,000 after purchasing an additional 2,274 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Medpace during the fourth quarter worth $4,084,000. Cerity Partners LLC boosted its holdings in shares of Medpace by 41.0% in the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after purchasing an additional 23,530 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Medpace by 24,930.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock valued at $56,936,000 after purchasing an additional 100,968 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of Medpace by 32.8% in the 4th quarter. UBS Group AG now owns 328,879 shares of the company’s stock valued at $184,715,000 after purchasing an additional 81,250 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.